It has been suggested that ACE2-mediated inhibition of the AT1R pathway, which is beneficial in the treatment of hypertension, may also increase the susceptibility to pulmonary and cardiovascular disease in patients with COVID-19 [17]. The gene discussed is ACE2; the disease is hypertensive disorder.